Figure 2

Median tremelimumab concentration-time profiles following a 1-hour intravenous infusion compared to the 5 hour infusion. The graph is in semi-logarithmic scale, with the 1-hour infusion data in 42 patients from study A3671022 in solid line and filled diamonds, compared to the data from the A3671008 study where 191 patients received tremelimumab with infusion times of 5–7 hours presented with a discontinuous line and open squares.